MeiraGTx Holdings plc Lease Obligation Incurred
MeiraGTx Holdings plc (MGTX) reported Lease Obligation Incurred of $22.93 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-07.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalLeaseObligationsIncurred · last filed 2019-11-07
- MeiraGTx Holdings plc lease obligation incurred for the quarter ending 2019-09-30 was -$1.53M.
- MeiraGTx Holdings plc lease obligation incurred for the quarter ending 2019-06-30 was $13.53M.
- MeiraGTx Holdings plc lease obligation incurred for the quarter ending 2019-03-31 was $10.93M.
- MeiraGTx Holdings plc lease obligation incurred for the quarter ending 2017-12-31 was $0.00.
- MeiraGTx Holdings plc lease obligation incurred for fiscal 2017 was $78.06K.
| Period end | Lease Obligation Incurred 3 month | Lease Obligation Incurred 6 month | Lease Obligation Incurred 9 month | Lease Obligation Incurred 12 month |
|---|---|---|---|---|
| 2019-09-30 | -$1.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $12.00M derived: sum of 2 quarters · filed 2019-11-07 | $22.93M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $13.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $24.46M 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | $10.93M 10-Q · filed 2019-05-14 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $0.00 derived: sum of 2 quarters · filed 2019-03-26 | $78.06K 10-K · filed 2019-03-26 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $78.06K 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $78.06K 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |